Capital Research Global Investors Acquires 3,383,559 Shares of ADMA Biologics Inc $ADMA

Capital Research Global Investors increased its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 104.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,637,472 shares of the biotechnology company’s stock after buying an additional 3,383,559 shares during the quarter. Capital Research Global Investors owned 2.79% of ADMA Biologics worth $121,067,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Boothbay Fund Management LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth $11,334,000. Tealwood Asset Management Inc. bought a new stake in shares of ADMA Biologics during the 4th quarter worth $1,315,000. American Century Companies Inc. lifted its position in shares of ADMA Biologics by 1.8% during the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after buying an additional 84,934 shares during the last quarter. Public Sector Pension Investment Board lifted its position in shares of ADMA Biologics by 14.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 930,800 shares of the biotechnology company’s stock worth $13,646,000 after buying an additional 116,867 shares during the last quarter. Finally, First Light Asset Management LLC lifted its position in shares of ADMA Biologics by 12.3% during the 3rd quarter. First Light Asset Management LLC now owns 1,069,233 shares of the biotechnology company’s stock worth $15,675,000 after buying an additional 117,137 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman acquired 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.90% of the company’s stock.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $8.06 on Tuesday. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.87 billion, a PE ratio of 11.85 and a beta of 0.73. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $22.37. The stock has a 50-day moving average price of $9.24 and a two-hundred day moving average price of $14.37.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. Analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current year.

Analyst Ratings Changes

ADMA has been the subject of several recent analyst reports. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Canaccord Genuity Group dropped their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Zacks Research downgraded ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Finally, Mizuho dropped their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $19.00.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.